Role of central mineralocorticoid binding sites in development of hypertension.
The possibility that central mineralocorticoid binding sites are involved in the development of mineralocorticoid hypertension was examined using chronic blockade of these sites with a specific mineralocorticoid receptor antagonist RU 28318 administered by intracerebroventricular (icv) infusion. The antagonist significantly attenuated the development of deoxycorticosterone acetate (DOCA)-salt hypertension, but the development of one-kidney, one-clip renal hypertension was not affected. This antihypertensive action was attributable to a central action, since intraperitoneal infusion of the same dose of mineralocorticoid antagonist did not alter the peak development of DOCA-salt hypertension. The icv infusion of RU 28318 did not change either the increase of fluid intake induced by DOCA-salt treatment or the pressor reactivity to centrally or peripherally injected arginine vasopressin and angiotensin II and peripherally administered phenylephrine. The antihypertensive action of icv infusion of the mineralocorticoid antagonist was associated with a reduction of neurogenic vasomotor tone and a restoration of impaired arterial baroreflexes. We conclude that functional integrity of central mineralocorticoid binding sites is required for the full development of DOCA-salt hypertension.
Janiak
P C
PC
Department of Pharmacology, University of Iowa, College of Medicine, Iowa City 52242.
Lewis
S J
SJ
Brody
M J
MJ
D000818:Animals; D001665:Binding Sites; D001921:Brain / Q000378:metabolism*; D003900:Desoxycorticosterone; D006973:Hypertension / Q000139:chemically induced*; D006978:Hypertension, Renovascular / Q000209:etiology*; D008297:Male; D008901:Mineralocorticoids / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D012965:Sodium Chloride
D008901:Mineralocorticoids; D003900:Desoxycorticosterone; D012965:Sodium Chloride